This is Merck's clinical trial protocol for Protocol V501-015-00 — the "FUTURE II" study, a large randomized, worldwide, placebo-controlled, double-blind Phase III trial (dated April 11, 2002) investigating the safety, immunogenicity, and efficacy of Merck's quadrivalent HPV vaccine (Gardasil, HPV types 6, 11, 16, 18 L1 virus-like particle vaccine) in preventing HPV 16/18-related CIN 2/3 (cervical dysplasia) or worse in women aged 16–23. It's a 140-page confidential/proprietary sponsor document covering background and rationale, study objectives and hypotheses, subject inclusion/exclusion criteria, study design and treatment plan, and detailed clinical procedures — the FUTURE II trial was one of the pivotal studies supporting Gardasil's eventual FDA approval.